BioCryst Pharmaceuticals (BCRX) vs Lycia Therapeutics (LYCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioCryst Pharmaceuticals is the larger company by market cap ($1.86 billion vs $1.72 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | LYCA |
|---|---|---|
| Share price | $7.22 | $33.07 |
| Market cap | $1.86B | $1.72B |
| 1-day change | -1.37% | +4.09% |
| YTD return | -7.44% | — |
| 1-year return | +3.59% | — |
| 5-year return | -42.15% | — |
| Forward P/E | 8.44 | — |
| EPS (TTM) | $-1.28 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | — |
| Revenue growth (YoY) | +94.10% | — |
| Net income (latest FY) | $263.86M | — |
| Gross margin | 97.82% | — |
| Operating margin | 38.98% | — |
| Net margin | 30.16% | — |
| 52-week high | $11.22 | $36.49 |
| 52-week low | $6.23 | $22.19 |
| Distance from 52-week high | -35.65% | -9.37% |
| Analyst consensus | buy | — |
| Avg. price target upside | +183.24% | — |
| Average volume | 4.97M | 432.72K |
| Shares outstanding | 257.30M | 52.09M |
| Employees | 435 | 31 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Lycia Therapeutics
LYCA stock →Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees
BCRX vs LYCA FAQ
Which is bigger, BioCryst Pharmaceuticals or Lycia Therapeutics?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $1.86B compared with $1.72B for Lycia Therapeutics (LYCA).
Are BioCryst Pharmaceuticals and Lycia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.